The growing disease burden and emergence of innovative new therapeutics means that the multi-billion dollar ophthalmic drug market is poised for near double digit compound growth over the next 5 years. There is enormous untapped potential for companies focusing on developing novel approaches to tackle age related macular degeneration, diabetic macular edema, glaucoma and other degenerative ocular conditions.
Focussing specifically on the challenges drug developers face in the development and delivery of clinically effective ocular drugs, the 2nd Annual Ophthalmic Drug Development Summit is your opportunity to fast-track your development efforts in this space.
Rather than covering early stage research or pipeline overviews, this meeting will unite leaders from Novartis, Genentech, Santen, Astellas and Spark Therapeutics to deliver granular, in-depth insights that will help you accelerate the progress of your ocular drug pipeline.
Time: 9:00 am to 5:00 pm
|Contact Person:||Customer Services|
|Organizer State/Province: (Outside US)|
|Organizer Country||Data not provided|
|Organizer Phone||020 3141 8700|
|Host Sponsor; Other Sponsors||Hanson Wade|
|Event sold out?||No|
|Multiple locations or dates?||No|
|Statistics available for most recent event held in:||NA|
|Average number in event attendance of:|
|Number in attendance of:|
|Is Registration contact information the same as Organizer Contact above?||Yes|
|Web Page |
|Can one register for your CE on your web site?||NA|
|Can registration be made by snail (regular) mail?||Yes|
|Online housing reservations:|| |
|Do you have additional written or AV materials for sale?||No|
|If so, are they available for non-attendees as well as those attending?||NA|
|Is full tuition necessary to ensure registration?||No|
|Will there be shuttle service available?||NA|
Brochure: https://go.evvnt.com/120560-1 ,